{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:14:18Z","timestamp":1751516058719,"version":"3.41.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011338","name":"AstraZeneca Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Heart failure (HF) is among the most prevalent health issues worldwide and is associated with high mortality. Adequate decongestion remain the main clinical challenge in HF management. Sodium glucose cotransporter-2 inhibitors (SGLT-2i) have been recently introduced as a new treatment option in patients with HF irrespective of left ventricular ejection fraction. Although the favorable effects of SGLT-2i are profoundly evident, the underlying mechanisms are not yet well understood. The aim of this study is to provide novel insights into the effects of dapagliflozin, a SGLT-2i with proven cardiovascular benefit, on blood volume profile and vascular function in HF patients who had a recent event of acute decompensated heart failure (ADHF).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Eighty adult patients with diagnosis of de novo or chronic HF (NYHA class II-IV), clinically stabilized after an ADHF event and with preserved renal function, who were not on treatment with SGLT-2i, are aimed to be included. The patients are randomized with 1:1 allocation to either dapagliflozin 10\u2009mg p.o. once daily or placebo in addition to guideline-directed medical therapy. The primary outcome is the mean change in plasma volume status (PVS) in the dapagliflozin group compared to placebo. PVS is assessed via optimized carbon monoxide rebreathing technique, a reliable and safe method to measure total hemoglobin mass and to estimate blood volume profile, i.e., blood volume, plasma volume and red blood cell volume. Secondary outcomes include differences between the two study groups regarding blood volume profile, micro- and macro-vascular function assessed by retinal vessel analysis and flow-mediated vasodilation, respectively, changes in body water distribution, quality of life, exercise capacity, echocardiographic and laboratory parameters.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The study has been approved by the Cantonal Ethics Committee Zurich (BASEC-Nr.:2020\u221201920, Swissmedic-Nr.:2020DR4175) and has been registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.ClinicalTrials.gov\" xlink:type=\"simple\">www.ClinicalTrials.gov<\/jats:ext-link>\u200c (NCT04869124). The results will be published in a peer-reviewed medical journal.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0325668","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T17:30:48Z","timestamp":1751477448000},"page":"e0325668","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2609-6330","authenticated-orcid":true,"given":"Konstantinos","family":"Bitos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6855-7768","authenticated-orcid":true,"given":"Natallia","family":"Laptseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina A.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias P.","family":"N\u00e4gele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sudano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas J.","family":"Flammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"3","key":"pone.0325668.ref001","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jchf.2017.08.023","article-title":"Anemia in heart failure: still relevant?","volume":"6","author":"N Grote Beverborg","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"5","key":"pone.0325668.ref002","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003610","article-title":"True anemia-red blood cell volume deficit-in heart failure: a systematic review","volume":"10","author":"D Montero","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"6","key":"pone.0325668.ref003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jchf.2016.01.005","article-title":"Volume overload profiles in patients with preserved and reduced ejection fraction chronic heart failure: are there differences? A pilot study","volume":"4","author":"WL Miller","year":"2016","journal-title":"JACC Heart Fail"},{"key":"pone.0325668.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cca.2014.10.027","article-title":"Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators","volume":"443","author":"A Buglioni","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"11","key":"pone.0325668.ref005","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.amjcard.2019.08.038","article-title":"Sodium glucose Co-transporter 2 inhibitors and heart failure","volume":"124","author":"RK Ghosh","year":"2019","journal-title":"Am J Cardiol"},{"issue":"21","key":"pone.0325668.ref006","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"JJV McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0325668.ref007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"M Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0325668.ref008","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"SD Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0325668.ref009","article-title":"Empagliflozin in heart failure with a preserved ejection fraction. Reply","volume":"386","author":"SD Anker","year":"2022","journal-title":"N Engl J Med"},{"issue":"36","key":"pone.0325668.ref010","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"37","key":"pone.0325668.ref011","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"TA McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"pone.0325668.ref012","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","article-title":"The Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit","volume":"10","author":"DK Patel","year":"2019","journal-title":"Diabetes Ther"},{"issue":"3","key":"pone.0325668.ref013","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2014.02.006","article-title":"In search of euvolemia in heart failure","volume":"2","author":"SD Katz","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"4","key":"pone.0325668.ref014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"SJ Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"pone.0325668.ref015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"9","key":"pone.0325668.ref016","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"PS Jhund","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"pone.0325668.ref017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ejhf.193","article-title":"Calculated plasma volume status and prognosis in chronic heart failure","volume":"17","author":"HZ Ling","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"pone.0325668.ref018","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cardfail.2018.11.019","article-title":"The optimal plasma volume status in heart failure in relation to clinical outcome","volume":"25","author":"P Martens","year":"2019","journal-title":"J Card Fail"},{"issue":"5","key":"pone.0325668.ref019","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ejhf.1407","article-title":"Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT","volume":"21","author":"JL Grodin","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"pone.0325668.ref020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00421-005-0050-3","article-title":"The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely","volume":"95","author":"W Schmidt","year":"2005","journal-title":"Eur J Appl Physiol"},{"issue":"3","key":"pone.0325668.ref021","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/00365513.2016.1271908","article-title":"Detection of blood volumes and haemoglobin mass by means of CO re-breathing and indocyanine green and sodium fluorescein injections","volume":"77","author":"S Keiser","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"key":"pone.0325668.ref022","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fphys.2018.01603","article-title":"Applying the optimized CO rebreathing method for measuring blood volumes and hemoglobin mass in heart failure patients","volume":"9","author":"C Ahlgrim","year":"2018","journal-title":"Front Physiol"},{"key":"pone.0325668.ref023","year":"2000"},{"issue":"1","key":"pone.0325668.ref024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/eurheartj\/ehx565","article-title":"Retinal microvascular dysfunction in heart failure","volume":"39","author":"MP N\u00e4gele","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"pone.0325668.ref025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/CIRCULATIONAHA.112.093245","article-title":"The assessment of endothelial function: from research into clinical practice","volume":"126","author":"AJ Flammer","year":"2012","journal-title":"Circulation"},{"issue":"18","key":"pone.0325668.ref026","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.110.956490","article-title":"Acetaminophen increases blood pressure in patients with coronary artery disease","volume":"122","author":"I Sudano","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"pone.0325668.ref027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1109\/TMI.2006.891477","article-title":"A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images","volume":"26","author":"V Gemignani","year":"2007","journal-title":"IEEE Trans Med Imaging"},{"issue":"3","key":"pone.0325668.ref028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ultrasmedbio.2007.08.006","article-title":"Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating","volume":"34","author":"V Gemignani","year":"2008","journal-title":"Ultrasound Med Biol"},{"issue":"4","key":"pone.0325668.ref029","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000452448","article-title":"Large artery stiffness assessment using SphygmoCor technology","volume":"4","author":"M Butlin","year":"2017","journal-title":"Pulse"},{"issue":"8","key":"pone.0325668.ref030","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0895-7061(02)02962-X","article-title":"Methods and devices for measuring arterial compliance in humans","volume":"15","author":"BM Pannier","year":"2002","journal-title":"Am J Hypertens"},{"issue":"21","key":"pone.0325668.ref031","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/eurheartj\/ehl254","article-title":"Expert consensus document on arterial stiffness: methodological issues and clinical applications","volume":"27","author":"S Laurent","year":"2006","journal-title":"Eur Heart J"},{"issue":"5","key":"pone.0325668.ref032","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"CP Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"pone.0325668.ref033","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3928\/0098-9134-19991201-10","article-title":"The Pittsburgh Sleep Quality Index (PSQI)","volume":"25","author":"C Smyth","year":"1999","journal-title":"J Gerontol Nurs"},{"issue":"12","key":"pone.0325668.ref034","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","article-title":"Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"18","author":"M Galderisi","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"pone.0325668.ref035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/ehjci\/jey042","article-title":"Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging","volume":"19","author":"LP Badano","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"pone.0325668.ref036","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1164\/rccm.167.2.211","article-title":"ATS\/ACCP Statement on cardiopulmonary exercise testing","volume":"167","author":"American Thoracic Society, American College of Chest Physicians","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0325668.ref037","volume-title":"Handbook of Dialysis","author":"JT Daugirdas","year":"2001"},{"key":"pone.0325668.ref038","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"D Longo","year":"2011"},{"issue":"12","key":"pone.0325668.ref039","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"CCJ Dekkers","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"pone.0325668.ref040","volume-title":"Sample size calculations for clustered and longitudinal outcomes in clinical research","author":"CHM Ahn","year":"2014"},{"issue":"3","key":"pone.0325668.ref041","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2229-3485.83221","article-title":"Intention-to-treat concept: a review","volume":"2","author":"SK Gupta","year":"2011","journal-title":"Perspect Clin Res"},{"issue":"12","key":"pone.0325668.ref042","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"MR Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"pone.0325668.ref043","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"V Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"pone.0325668.ref044","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"M Packer","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"pone.0325668.ref045","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00392-018-1390-4","article-title":"Correction to: prognostic value of estimated plasma volume in acute heart failure in three cohort studies","volume":"108","author":"M Kobayashi","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"21","key":"pone.0325668.ref046","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14222","article-title":"Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction","volume":"7","author":"D Montero","year":"2019","journal-title":"Physiol Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T17:30:56Z","timestamp":1751477456000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325668"}},"subtitle":[],"editor":[{"given":"Habib","family":"Yaribeygi,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325668","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}